Rahul Singhvi, Sc.d., Mba
MD
immunology
Immunocellular Therapeutics
Cambodia
Biography
Dr. Singhvi was appointed a director in 2010. He is the Chief Operating Officer of Takeda Vaccines, Inc. and is responsible for Takeda’s global vaccine operations. He has deep experience in both vaccine development and manufacturing. Before joining Takeda, Dr. Singhvi was President and CEO of Novavax, a biopharmaceutical company focused on developing novel, highly potent recombinant vaccines. Prior to joining Novovac, Dr. Singhvi served in various positions with Merck & Co., Inc., culminating as Director of the Merck Manufacturing Division, where he helped develop several vaccines, including Zostavax® the only vaccine on the market to prevent shingles.
Research Interest
Dr. Singhvi was appointed a director in 2010. He is the Chief Operating Officer of Takeda Vaccines, Inc. and is responsible for Takeda’s global vaccine operations. He has deep experience in both vaccine development and manufacturing. Before joining Takeda, Dr. Singhvi was President and CEO of Novavax, a biopharmaceutical company focused on developing novel, highly potent recombinant vaccines. Prior to joining Novovac, Dr. Singhvi served in various positions with Merck & Co., Inc., culminating as Director of the Merck Manufacturing Division, where he helped develop several vaccines, including Zostavax® the only vaccine on the market to prevent shingles.
